News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,742 Results
Type
Article (13566)
Company Profile (110)
Press Release (247066)
Section
Business (87936)
Career Advice (461)
Deals (15324)
Drug Delivery (63)
Drug Development (36521)
Employer Resources (49)
FDA (6259)
Job Trends (6182)
News (150008)
Policy (14006)
Tag
Academia (435)
Alliances (23074)
Alzheimer's disease (347)
Approvals (6250)
Artificial intelligence (58)
Bankruptcy (143)
Best Places to Work (4307)
Biosimilars (39)
Biotechnology (44)
Breast cancer (40)
Cancer (286)
Career advice (405)
Cell therapy (39)
Clinical research (30326)
Collaboration (129)
Compensation (55)
COVID-19 (746)
C-suite (49)
Data (290)
Diabetes (47)
Diagnostics (1230)
Drug pricing (56)
Earnings (31447)
Employer resources (43)
Events (36639)
Executive appointments (145)
FDA (6422)
Funding (91)
Gene therapy (58)
GLP-1 (287)
Government (1264)
Healthcare (3517)
Infectious disease (763)
Inflammatory bowel disease (45)
Interviews (58)
IPO (5808)
Job creations (2049)
Job search strategy (372)
Layoffs (166)
Legal (3409)
Lung cancer (44)
Manufacturing (85)
Medical device (1260)
Medtech (1262)
Mergers & acquisitions (9535)
Metabolic disorders (154)
Neuroscience (436)
NextGen Class of 2024 (1580)
Non-profit (589)
Northern California (388)
Obesity (96)
Opinion (108)
Patents (51)
People (28405)
Pharmaceutical (64)
Phase I (7886)
Phase II (12823)
Phase III (11526)
Pipeline (134)
Podcasts (39)
Policy (43)
Postmarket research (1399)
Preclinical (3161)
Radiopharmaceuticals (116)
Rare diseases (82)
Real estate (2629)
Regulatory (9801)
Research institute (562)
Resumes & cover letters (55)
Southern California (398)
Startups (1624)
United States (3905)
Vaccines (109)
Weight loss (76)
Date
Today (63)
Last 7 days (335)
Last 30 days (1077)
Last 365 days (12667)
2024 (11100)
2023 (14244)
2022 (19556)
2021 (20069)
2020 (19033)
2019 (14887)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (39)
Asia (19753)
Australia (2552)
California (907)
Canada (560)
China (100)
Connecticut (37)
Europe (38697)
Florida (130)
Illinois (102)
Indiana (81)
Kansas (51)
Maryland (146)
Massachusetts (802)
Minnesota (50)
New Jersey (384)
New York (251)
North Carolina (269)
Northern California (388)
Pennsylvania (265)
South America (498)
Southern California (398)
Texas (122)
Virginia (37)
Washington State (66)
260,742 Results for "eloxx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation (ODD) for ELX-02.
April 16, 2024
·
8 min read
Business
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013.
March 13, 2024
·
7 min read
Press Releases
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
July 12, 2024
·
7 min read
Business
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended September 30, 2023, and provided a business update.
November 13, 2023
·
11 min read
Deals
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Eloxx Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock.
September 19, 2023
·
7 min read
Drug Development
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided an update on the continued advancement of ELX-02 for the treatment of Alport syndrome with nonsense mutations, including additional positive results from its Phase 2 clinical study evaluating ELX-02, as well as an update on ZKN-013.
September 7, 2023
·
7 min read
Genetown
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
Eloxx Pharmaceuticals, Inc., a leader in ribosomal RNA-targeted genetic therapies for rare diseases, announced that it will host an Investor and Analyst call and webcast on Tuesday, June 27, 2023 at 11:30 am ET.
June 21, 2023
·
5 min read
Business
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended June 30, 2023, and provided a business update.
August 14, 2023
·
13 min read
Drug Development
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported results from an assessment of patient biopsies by NIPOKA GmbH (Nipoka).
October 9, 2023
·
7 min read
Drug Development
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported additional independent confirmation on the positive TEM assessment results from its proof-of-concept Phase 2 open-label clinical trial (NCT05448755) of ELX-02 for the treatment of Alport syndrome after eight weeks of treatment.
September 18, 2023
·
6 min read
1 of 26,075
Next
